A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The proposed trial provides a unique opportunity in that it combines genomic, proteomic, and
pharmacogenomic assessments in patients receiving the most commonly used chemotherapies for
advanced breast cancer. To date no other trial has analyzed gene and protein expression at
the same time points in the same patient, combined with clinical outcome. Similar to previous
attempts to predict response based on expression of a single gene or protein, the researchers
expect that neither genomic or proteomic profiling alone will be sufficient to optimize
therapy. Rather, the researchers expect an iterative process that combines information
gleaned from both platforms, modified to avoid toxicity based on pharmacogenomics.
Details
Lead Sponsor:
Hoosier Cancer Research Network
Collaborators:
Indiana University School of Medicine United States Department of Defense Walther Cancer Institute